2024
Secondary Prevention in Patients With Stroke Versus Myocardial Infarction: Analysis of 2 National Cohorts
Rivier C, Acosta J, Leasure A, Forman R, Sharma R, de Havenon A, Spatz E, Inzucchi S, Kernan W, Falcone G, Sheth K. Secondary Prevention in Patients With Stroke Versus Myocardial Infarction: Analysis of 2 National Cohorts. Journal Of The American Heart Association 2024, 13: e033322. PMID: 38639369, PMCID: PMC11179946, DOI: 10.1161/jaha.123.033322.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntihypertensive AgentsBlood PressureCross-Sectional StudiesFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsPractice Guidelines as TopicRisk AssessmentRisk FactorsSecondary PreventionStrokeUnited KingdomUnited StatesConceptsMyocardial infarctionPrevention scoreSecondary preventionImplementation of preventive therapyNational cohortUK BiobankAntiplatelet therapy useGuideline-directed therapyPrevention profilesBlood pressure controlAdherence to guideline-directed therapyLow-density lipoprotein controlNeighborhood deprivation levelHistory of strokeVascular risk profileStatin useAntiplatelet useTherapy usePreventive therapyComparison to participantsPrevention criteriaCross-sectional analysisBlood pressurePatientsPressure control
2022
Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction DELIVER
Selvaraj S, Vaduganathan M, Claggett B, Miao Z, Fang J, Vardeny O, Desai A, Shah S, Lam C, Martinez F, Inzucchi S, de Boer R, Petersson M, Langkilde A, McMurray J, Solomon S. Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction DELIVER. JACC Heart Failure 2022, 11: 76-89. PMID: 36599553, DOI: 10.1016/j.jchf.2022.09.002.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBenzhydryl CompoundsBlood PressureFemaleHeart FailureHumansMaleMiddle AgedStroke VolumeConceptsSystolic blood pressureBlood pressureHeart failureSBP categoriesEjection fractionPrimary outcomeKansas City Cardiomyopathy Questionnaire total symptom scoreTreatment effectsSodium-glucose cotransporter 2 inhibitorsBaseline systolic blood pressureBlood pressure-lowering effectHigher systolic blood pressureHigher heart failureClass I recommendationCotransporter 2 inhibitorsPressure-lowering effectTotal symptom scoreCardiovascular outcomesAdverse eventsAntihypertensive effectSecondary outcomesStroke riskI recommendationSymptom scoresCardiovascular disease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply